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Abstract
Background: It is widely recognized that only a handful of drugs are available against soil-transmitted helminthiasis, all of
which are characterized by a low efficacy against Trichuris trichiura, when administered as single doses. The re-evaluation of
old, forgotten drugs is a promising strategy to identify alternative anthelminthic drug candidates or drug combinations.
Methodology: We studied the activity of the veterinary drug oxantel pamoate against Trichuris muris, Ancylostoma
ceylanicum and Necator americanus in vitro and in vivo. In addition, the dose-effect of oxantel pamoate combined with
albendazole, mebendazole, levamisole, pyrantel pamoate and ivermectin was studied against T. muris in vitro and additive
or synergistic combinations were followed up in vivo.
Principal Findings: We calculated an ED50 of 4.7 mg/kg for oxantel pamoate against T. muris in mice. Combinations of
oxantel pamoate with pyrantel pamoate behaved antagonistically in vitro (combination index (CI) = 2.53). Oxantel pamoate
combined with levamisole, albendazole or ivermectin using ratios based on their ED50s revealed antagonistic effects in vivo
(CI = 1.27, 1.90 and 1.27, respectively). A highly synergistic effect (CI = 0.15) was observed when oxantel pamoate-
mebendazole was administered to T. muris-infected mice. Oxantel pamoate (10 mg/kg) lacked activity against Ancylostoma
ceylanicum and Necator americanus in vivo.
Conclusion/Significance: Our study confirms the excellent trichuricidal properties of oxantel pamoate. Since the drug lacks
activity against hookworms it is necessary to combine oxantel pamoate with a partner drug with anti-hookworm properties.
Synergistic effects were observed for oxantel pamoate-mebendazole, hence this combination should be studied in more
detail. Since, of the standard drugs, albendazole has the highest efficacy against hookworms, additional investigations on
the combination effect of oxantel pamoate-albendazole should be launched.
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Introduction
Infections with the three major soil-transmitted helminth (STH)
species, Ascaris lumbricoides, Trichuris trichiura and the hookworms
Necator americanus and Ancylostoma duodenale are among the most
common parasitic diseases in areas of rural poverty in developing
countries [1]. In regions where soil-transmitted helminthiasis is
endemic, preventive chemotherapy, i.e. regular anthelminthic
drug administration to all people at risk of morbidity, is one of the
key strategies [2]. In 2009 it was estimated that 204 million school-
aged children were treated for soil-transmitted helminthiasis [3].
The benzimidazoles, albendazole and mebendazole are the most
widely used drugs in preventive chemotherapy programs. At
present, two alternative drugs, pyrantel pamoate and levamisole
are available but currently have a less prominent role since they
require weight-based dosing [4]. Despite their excellent safety
profile, these drugs have serious limitations with regard to their
efficacy. When delivered as a single dose, as in preventive
chemotherapy programs, all four compounds have a limited effect
against infections with T. trichiura as shown in a recent meta-
analysis [5]. In addition, drug resistance is a concern [4;6]. Efforts
are therefore ongoing to discover and develop the next generation
of anthelminthic drugs [7]. Promising strategies to identify
potential anthelminthic drug candidates are to assess compounds
derived from animal health, to re-evaluate forgotten compounds
and to thoroughly study drug combinations [7,8].
Oxantel is the meta-oxyphenol analog of pyrantel. It was
discovered in the early 1970s by Pfizer and showed high activity in
T. muris-infected mice and T. vulpis-infected dogs [9,10]. Subse-
quent exploratory clinical trials demonstrated that the drug was
safe and effective in the treatment of trichuriasis [11–14]. For
example, complete cure was observed in 10 T. trichiura-infected
patients treated with 20 mg/kg oxantel pamoate [11]. In
veterinary medicine oxantel pamoate was later combined with
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pyrantel pamoate, which has, with the exception of activity against
Trichuris spp., a broad spectrum of activity against different
nematodes [15]. Today oxantel-pyrantel is widely available as a
dewormer for dogs and cats. The combination of oxantel-pyrantel
was also evaluated in a few clinical trials against human STH
infections [13,16–19]. For example, a decade ago oxantel-pyrantel
(10 mg/kg) was tested in school-aged children on Pemba island.
The combination achieved cure rates of 38.2% and 12.7% against
infections with T. trichiura and hookworms, respectively [19]. To
our knowledge, despite the interesting trichuricidal properties of
oxantel, combinations of this drug with other recommended
anthelminthic drugs have not been evaluated to date.
The aim of the present study was to investigate the trichuricidal
potential of oxantel pamoate combined with the four WHO
recommended anthelminthic drugs for the treatment of hook-
worm, T. trichiura and A. lumbricoides infections (albendazole,
mebendazole, levamisole or pyrantel pamoate) as well as
combinations of ivermectin and oxantel pamoate. Ivermectin,
the first line drug for strongyloidiasis, is known to have
trichuricidal properties and combinations of albendazole-ivermec-
tin and mebendazole-ivermectin have been tested clinically [20].
In a first step the EC50 (ED50) values of oxantel pamoate against T.
muris were determined in vitro and in vivo. Next to oral
administration we also tested the activity of intraperitoneal oxantel
pamoate in mice. We then elucidated whether oxantel pamoate
combined with albendazole, mebendazole, ivermectin, levamisole
or pyrantel pamoate interacts in an additive, antagonistic or
synergistic manner in vitro using the combination index equation
[21]. Additive and synergistic combinations were followed up in
vivo. In addition, the activity of oxantel pamoate was studied
against A. ceylanicum and N. americanus in vitro and in vivo.
Materials and Methods
Drugs
Albendazole and levamisole were purchased from Fluka (Buchs,
Switzerland), oxantel pamoate, mebendazole, ivermectin and
pyrantel pamoate were obtained from Sigma-Aldrich (Buchs,
Switzerland). Note that, the pamoate salts of oxantel and pyrantel
contain only 35.8% and 34.7% of the active ingredients, oxantel
and pyrantel base, respectively.
For in vitro studies, drug stocks (5–10 mg/ml) were prepared in
100% DMSO (Sigma-Aldrich, Buchs, Switzerland) and stored at
4uC pending usage. For in vivo studies, the drugs were suspended in
10% Tween 80 [80% EtOH (70:30 v/v)] (Buchs, Switzerland) and
90% dH2O shortly before treatment.
Animals
Four week-old female C57BL/10 mice and 3 week-old male
Syrian golden hamsters were purchased from Charles River
(Blackthorn, UK and Sulzfeld, Germany, respectively). Before
infection, animals were allowed to acclimatize for one week in our
animal facility. They were kept in groups of maximum ten (mice)
or three (hamsters) in macrolon cages with free access to water and
rodent food pellets (Rodent Blox from Eberle NAFAG, Gossau,
Switzerland).
Ethics statement
Experiments were performed in an attempt to comply with the
3R rules for animal experiments. The current study was approved
by the cantonal veterinary office Basel-Stadt (Switzerland) based
on Swiss cantonal and national regulations (permission no. 2070).
Parasites and infections
Trichuris muris. The life cycle of T. muris has been
maintained at the Swiss TPH since January 2010 [22–25]. Mice
were treated with dexamethasone (1 mg/l, dexamethasone-water
soluble, Sigma-Aldrich) supplied with the drinking water 2 days
before infection onwards and were infected orally with 200
embryonated T. muris eggs.
Ancylostoma ceylanicum and Necator americanus. The
A. ceylanicum and N. americanus life cycles have been maintained at
the Swiss TPH since June 2009 and April 2011, respectively, as
described previously [25–28]. Hamsters were treated with 0.5 mg/
l dexamethasone in the drinking water, 2 days before infection
onwards. They were infected orally with 150 L3 (A. ceylanicum) or
subcutaneously with 250 L3 (N. americanus). Hamsters assigned to in
vivo studies were not immunosuppressed and were infected with
300 L3.
In vitro studies with Trichuris muris
Oxantel monotherapy. Fourth-stage larvae (L4) (days 26–28
p.i.) were collected from the mice intestines (binocular, magnifi-
cation 166) and transferred in groups of 3–4 into each well of a
96-well plate containing 100 ml pre-warmed RPMI medium
[10.44 g RPMI 1640 (Gibco, Basel, Switzerland), 5 g albumax
H (Gibco), 5.94 g HEPES (Sigma-Aldrich) and 2.1 g sodium
bicarbonate (Sigma-Aldrich) in 1 l dH2O] supplemented with 5%
v/v amphotericin B (250 mg/ml, Sigma-Aldrich) and 1% v/v
penicillin-streptomycin (10’000 U/ml penicillin+10 mg/ml strep-
tomycin, Sigma-Aldrich). Next, 100 ml of an oxantel pamoate
solution were added to obtain 0.15–600 mg/ml (final concentra-
tions) and the plate was incubated at 37uC and 5% CO2 for
72 hours. Control worms were incubated in medium with the
highest DMSO concentration used in the test (1% v/v). After 24,
48 and 72 hours of incubation the viability of the worms was
evaluated according to a motility scale from 3 to 0 (3 = normal,
100% motility, 0 = dead). Assays were conducted in duplicate.
Combination chemotherapy studies. Drug combination
assays were carried out as described for single drug assays, with
slight alterations. Three to 4 adult worms were transferred into
Author Summary
The roundworm Ascaris lumbricoides, the whipworm
Trichuris trichiura and the two hookworm species Ancylos-
toma duodenale and Necator americanus are responsible
for the most common infections worldwide and place
more than 5 billion people at risk. To control these
infections, at risk populations are treated regularly with
anthelminthic drugs, mostly albendazole and mebenda-
zole. Since both drugs have a low therapeutic effect
against T. trichiura, alternative drugs should be discovered
and developed. Possible strategies are to re-evaluate
forgotten compounds and to thoroughly study drug
combinations. We evaluated the activity of the ‘‘old’’,
veterinary drug oxantel pamoate against T. muris, Ancy-
lostoma ceylanicum and Necator americanus in vitro and in
vivo. In addition, we studied the activity of oxantel
pamoate combinations with the four standard treatments
for soil-transmitted helminthiasis. Our results confirm that
oxantel pamoate has excellent trichuricidal properties. We
show that the drug lacks activity against hookworms. It is
therefore necessary to combine oxantel pamoate with an
anti-hookworm drug. Synergistic effects were observed
with oxantel pamoate-mebendazole in our study. Addi-
tional preclinical studies should be launched with oxantel
pamoate-mebendazole as well as oxantel pamoate-alben-
dazole, since albendazole is the most widely used and
efficacious anti-hookworm drug.
Oxantel against Trichuris muris and Hookworms
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each well of a 48-well plate containing 500 ml pre-warmed
supplemented RPMI medium. Then, 250 ml of the drug solution
#1 and 250 ml of the drug solution#2 were added at a constant dose
ratio based on the calculated IC50 values (inhibitory concentration
50%) and 2-fold dilutions were carried out up and down. In more
detail, the following combinations were tested: 2IC50:2IC50,
IC50:IC50, 0.5IC50:0.5IC50 and 0.25IC50:0.25IC50. Since for alben-
dazole, mebendazole and ivermectin no IC50 value could be
calculated (IC50s.200 mg/ml) [29], a concentration of 400 mg/ml
was selected as IC50 value. A combination index (CI) was calculated
to characterize the interaction of each combination: synergism
(CI,1), antagonism (CI.1) and additive effect (CI=1) [21].
In vitro studies with Ancylostoma ceylanicum and Necator
americanus
Oxantel monotherapy. In vitro studies with A. ceylanicum and
N. americanus third-stage larvae (L3) and adult worms were
conducted as described recently [25]. Briefly, in a 96-well plate
(Costar), 30 L3 per well were incubated for 72 hours at room-
temperature in 200 ml HBSS medium supplemented with 10% v/
v amphotericin B (250 mg/ml, Sigma-Aldrich), 1% v/v penicillin-
streptomycin (10’000 U/ml penicillin+10 mg/ml streptomycin,
Sigma-Aldrich) containing oxantel pamoate dilutions (1, 10 and
100 mg/ml, final concentrations). The larval survival was deter-
mined microscopically (magnification 206) following addition of
hot water (,80uC) and exposure to microscope light.
Two to 3 adult worms, collected from the hamsters intestines
(binocular, magnification 166), were incubated per well in 48-well
plates for 72 hours in 1 ml supplemented HBSS medium and 10%
v/v fetal calf serum containing oxantel pamoate dilutions (ranging
from 0.1 to 100 mg/ml) at 37uC, 5% CO2. The motility was
determined microscopically (magnification 206) using a viability
scale ranging from 2 (normal viability, 100% motility) to 0 (death).
Control worms were incubated with the highest DMSO concen-
tration used in the test (2% v/v). Assays were conducted in triplicate.
In vivo studies
Trichuris muris. Each animal was checked for the presence
of eggs in the stools on day 40 p.i. and assigned to treatment or
control groups (n = 4 mice per group) and treated with a single oral
drug dose on the following day. Oxantel pamoate was adminis-
tered at 10 mg/kg, 5 mg/kg, 2.5 mg/kg and 1 mg/kg. Two
groups of mice were treated intraperitoneally with 10 mg/kg
oxantel pamoate and 10 mg/kg ivermectin. Expelled worms,
recovered from stools collected for up to 72 hours after treatment,
were counted. At dissection, worms remaining in the gut 7 days
posttreatment were collected and counted. Worm burden arith-
metic means were calculated for each treatment and control
group. Worm burden reductions (WBRs) and worm expulsion
rates (WERs) were calculated as described previously [25]. Drug
combinations revealing synergism in vitro (CI,1) (oxantel pamo-
ate-albendazole, oxantel pamoate-levamisole, oxantel pamoate-
mebendazole and oxantel pamoate-ivermectin), were tested in vivo
using a constant dose ratio. The ratio of the ED50s (effective dose
50%) of each drug was chosen as starting dose (ED50:ED50). If the
treatment reduced the worm burden by more than 75% (threshold
for additivity when the dose effect curves for both drugs are
hyperbolic [21]), the drug doses were divided in half. ED50 values
of the partner drugs were 345 mg/kg for albendazole, 79 mg/kg
for mebendazole (both values determined in the frame of the
present work), 4 mg/kg for ivermectin, and 46 mg/kg levamisole
[29].
Ancylostoma ceylanicum and Necator americanus. The
experiments were carried out as described recently [25,30].
Briefly, the fecal egg burden was established on days 21 and 22
p.i. (A. ceylanicum) and 46 and 47 (N. americanus) and treatment and
control groups formed on the basis of arithmetic mean fecal egg
burden. Hamsters were treated with a single oral dose of 10 mg/
kg oxantel pamoate on the following day. Animals left untreated
served as controls. The complete stools were collected from each
hamster for up to 48 hours posttreatment and searched for
expelled worms (binocular, magnification 166). WERs were
calculated.
Statistical analyses
All the data obtained were analyzed by Excel (Microsoft Office,
2007). In vitro data obtained from the individual motility assays
were averaged and normalized to the controls. IC50s (median-
effect dose), defined as the concentration of a drug required to
decrease the mean worm’s motility to 50% at the 72 hour time
point, were calculated with the CompuSyn software (CompuSyn,
version 3.0.1). The combination index (CI) was calculated for the
combination chemotherapy data with CompuSyn. To test the
significance of the WBRs in vivo, the Kruskal-Wallis (several
treatment doses vs. controls) or the Mann-Whitney U test (one
treatment dose vs. control) was applied, using StatsDirect (version
2.4.5; StatsDirect Ltd; Cheshire, UK).
Results
In vitro studies with T. muris
Oxantel monotherapy. Temporal drug effects of different
oxantel pamoate concentrations over the incubation period of
72 hours are depicted in Figure 1. Exposure of T. muris L4 to 0.15
and 0.3 mg/ml oxantel pamoate achieved only a negligible effect
(mean motilities of 76.7% (SD 631.3%) and 83.3% (SD
623.3%), respectively) on the worms 24–72 hours posttreatment.
Incubation of T. muris L4 for 24–72 hours with 0.6–600 mg/ml
oxantel pamoate resulted in strongly reduced viabilities within
24 hours but did not kill the worms. Control worms showed
normal movements over the entire incubation period. We
calculated an IC50 of 2.35 mg/ml for oxantel pamoate (corre-
sponding to 0.78 mg/ml for the free base oxantel) on T. muris L4
(Table 1).
Trichuris muris combination chemotherapy. Oxantel
pamoate was combined with albendazole, mebendazole, pyrantel
pamoate, ivermectin or levamisole using ratios based on their
IC50s and T. muris adults were exposed simultaneously to one of
these combinations. The results are presented in Table 1 and dose
response relationships of the combinations depicted in Figure 2.
Synergistic effects were observed for four of the combinations,
namely oxantel pamoate-mebendazole (CI = 0.06), oxantel pam-
oate-ivermectin (CI= 0.27), oxantel pamoate-albendazole
(CI = 0.37) and oxantel-pamoate levamisole (CI = 0.46). An
antagonistic interaction was found when oxantel pamoate was
combined with pyrantel pamoate (CI = 2.53). Worms exposed to
this combination were only affected at the two highest concentra-
tion ratios (2IC50:2IC50 and IC50:IC50) and showed normal
viability at the two lowest concentration ratios examined
(0.5IC50:0.5IC50 and 0.25IC50:0.25IC50).
In vitro studies with Ancylostoma ceylanicum. A. ceyla-
nicum L3 incubated with oxantel pamoate revealed high survival
rates (92.9%, SD 60.01% at 1 mg/ml, 100%, SD 60.0% at
10 mg/ml and 95.3%, SD 60.07% at 100 mg/ml), compared to
controls. Similarly, adult worms were only weakly affected by the
drug, showing an average motility of 100% (SD60.0%) at 0.1 and
1 mg/ml and 83.5% (SD629.0%) at 10 and 100 mg/ml compared
to controls (motility of 100% (SD 60.0%)).
Oxantel against Trichuris muris and Hookworms
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In vitro studies with Necator americanus. N. americanus L3
incubated with oxantel pamoate revealed high survival rates
(100%, SD 60.05% at 0.1 mg/ml, 97.7%, SD 60.04% at 1 mg/
ml, 97.1%, SD 60.003% at 10 mg/ml and 96.6%, SD 60.0% at
100 mg/ml), compared to controls. In contrast, adult worms were
markedly affected by the drug, resulting in an average motility of
100% (SD 60.0%) at 0.1 mg/ml, 50% (SD 625.0%) at 1 mg/ml,
62.5% (SD 640.5%) at 10 mg/ml and only 12.5% (SD 625.0%)
at 100 mg/ml compared to controls (motility of 100% (SD
60.0%)). An IC50 of 11.80 mg/ml (r = 0.89) was calculated for
oxantel pamoate on N. americanus adult worms (Table 1).
In vivo studies with Trichuris muris
Oxantel monotherapy. Oxantel pamoate displayed a high
activity against T. muris in vivo, with an ED50 of 4.71 mg/kg. In
more detail, a WBR of 92.5% and WER of 88.4% were achieved
after administration of 10 mg/kg (Table 2). Administration of
5 mg/kg resulted in a WBR of 81.1% and a WER of 78.2%. A
low activity was observed with oxantel pamoate at 2.5 mg/kg
(WER=24.3%, WBR=13.5%) and no effect was observed when
mice were treated with 1 mg/kg (WER=1.5%, WBR=0%). The
worm burden in orally oxantel pamoate treated mice was
significantly different from untreated mice (P=0.041). An
Figure 1. Temporal effect of different concentrations of oxantel pamoate on the viability of T. muris. T. muris were exposed
concentrations of 0.15–600 mg/ml oxantel pamoate and examined 24, 48 and 72 hours post-incubation. Data derived from two independent
experiments.
doi:10.1371/journal.pntd.0002119.g001
Table 1. In vitro activity of oxantel pamoate against T. muris, A. ceylanicum and N. americanus.
Drugs IC50 (r)
T. muris L4 A. ceylanicum N. americanus
IC50 (r)
Combination
index (CI) at IC50 L3 Adults L3 Adults
Oxantel pamoate 2.35 (0.68) – .100 (n.d.) .100 (n.d.) .100 (n.d.) 11.80 (0.89)
Oxantel pamoate-albendazole 159.61 (0.87) 0.37 – – – –
Oxantel pamoate-mebendazole 27.95 (0.87) 0.06 – – – –
Oxantel pamoate-levamisole 2.93 (0.99) 0.46 – – – –
Oxantel pamoate-pyrantel pamoate 67.13 (0.90) 2.53 – – – –
Oxantel pamoate-ivermectin 116.86 (0.94) 0.27 – – – –
IC50 median effect dose. r = linear correlation coefficient of the median-effect plot, indicating the goodness of fit. r$0.85 indicates a satisfactory fit. IC50s of albendazole,
mebendazole, levamisole, pyrantel pamoate, and ivermectin have been published elsewhere [25]. n.d. = not determined.
doi:10.1371/journal.pntd.0002119.t001
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intraperitoneal treatment of 10 mg/kg lacked activity against T.
muris (both WER and WBR=0%). For comparison, 10 mg/kg
ivermectin given intraperitoneally resulted in a worm burden
reduction of 93.5%.
Combination chemotherapy. The four drug combinations
that displayed synergistic effects in vitro were followed up in vivo
(Table 2). Simultaneous treatment of T. muris-infected mice with a
combination of oxantel pamoate and albendazole using the
approximate ED50 doses resulted in a WBR of 76.6%, while
combining 0.5ED50s was inefficacious (WBR=0%). The combi-
nation was modeled as antagonistic (CI = 1.90). A synergistic
interaction was found for the combination oxantel pamoate-
mebendazole, as illustrated by a combination index of 0.15. A
WBR of 88.8% was achieved combining both drugs using the
ED50 doses and a still moderate WBR of 58.2% was observed
when doses of 0.63 mg/kg oxantel pamoate and 10 mg/kg
mebendazole (1/8 ED50s) were administered. Oxantel pamoate
combined with ivermectin achieved a WBR of 84.8% at the
highest dose tested (ED50:ED50 (5 and 4 mg/kg) of oxantel
pamoate and ivermectin, respectively), but the combination at
0.5ED50:0.5ED50 only produced a worm burden reduction of
37.5%. The combination dose-effect analysis yielded antagonistic
properties for the oxantel pamoate-ivermectin combination
(CI = 1.27). Finally, while the combination of oxantel pamoate
and levamisole at the ED50:ED50 removed most of the worms
(WBR=82.0%, WER=71.7%), using half of the dosage reduced
the worm burden by less than 50% (WBR=34.3%,
WER=31.1%). The overall behavior of the combination of
oxantel pamoate and levamisole was found to be antagonistic
(CI = 1.27).
In vivo studies with A. ceylanicum and N.
americanus. Oxantel pamoate exerted no effect on A. ceylanicum
in vivo following a single dose treatment of 10 mg/kg, illustrated by
a WER of 0% (data not shown). The same oral treatment (10 mg/
kg) in the N. americanus model resulted in a very low WER of 10.3%
(data not shown).
Discussion
Since the introduction of albendazole, mebendazole, levamisole,
and pyrantel pamoate in the human armamentarium to treat STH
infections 3–4 decades ago, successes in the discovery and
development of a novel nematocidal drug have been limited.
The danger of resistance development therefore raises concern for
the availability of effective therapies in the future. Furthermore, all
four above-mentioned drugs have a limited activity against
Trichuris spp when administered as single oral doses. To accelerate
the discovery of novel anthelminthic treatments potential drug
candidates have recently been examined in vitro, in vivo and in
clinical trials. Disappointingly, nitazoxanide, a potential drug
candidate identified through systematic literature searches [7] as
well as a combination of albendazole and nitazoxanide revealed
low trichuricidal activity in a randomized placebo controlled trial
on Pemba [31]. Furthermore, monepantel, a safe nematocidal
drug recently marketed for veterinary use showed a very poor
activity against Ascaris suum and T. muris in vitro and in vivo [25].
Hence, neither nitazoxanide nor monepantel can be recom-
mended for the treatment of infections with STH.
In the present work, another potential candidate, oxantel
pamoate, widely used in veterinary medicine was evaluated against
T. muris and hookworms in vitro and in vivo. Note that one limitation
of our study (and helminth drug discovery in general), is that in vitro
testing relied on motility scoring using microscopy, which is a
subjective examination procedure [32].
Oxantel pamoate revealed an excellent trichuricidal activity in
mice. We calculated an ED50 of 4.7 mg/kg in T. muris-infected
mice. A similarly low ED50 of 1.7 mg/kg was reported previously
in this model [33]. For comparison, the WHO recommended
drugs for the treatment of STH infections are characterized by
much higher ED50 values against T. muris in vivo, namely 345 mg/
kg for albendazole, 79 mg/kg for mebendazole, 46 mg/kg for
levamisole and .300 mg/kg for pyrantel pamoate [25,30].
Ivermectin, used in the treatment of strongyloidiasis and filarial
infections, displayed a comparable ED50 value of 4 mg/kg in our
T. muris model [29]. A dose of 10 mg/kg oxantel pamoate
administered intraperitoneally lacked activity in T. muris-infected
mice. For comparison, the same i.p. dose of ivermectin resulted in
a high reduction of the worm load (.93%). This demonstrates
that in contrast to ivermectin oxantel pamoate does not kill the
worm via the blood stream.
Oxantel pamoate lacked in vivo activity against both hookworm
species A. ceylanicum and N. americanus. This finding is in line with a
previous study in A. caninum-infected mice [34]. Interestingly, N.
americanus adults were affected by the drug in vitro while no activity
was observed on A. ceylanicum. To our knowledge, the activity of
oxantel pamoate against hookworms has not been studied in
humans.
Oxantel pamoate showed also no effect against the third major
soil-transmitted helminth species, A. lumbricoides in humans (all 53
patients treated with oxantel revealed Ascaris eggs in the stools
collected posttreatment regardless of the dose administered) [11].
It is therefore necessary to combine oxantel pamoate with a
partner drug with a therapeutic profile that covers roundworms
and hookworms. In the present work we have, for the first time,
thoroughly evaluated the potential of oxantel pamoate in drug
combinations. This work builds on a series of laboratory
investigations on the potential of combination chemotherapy for
the treatment of STH infections. We have for example recently
examined combinations of marketed drugs in in vitro and in vivo
studies against T. muris [8].
Interestingly, antagonistic effects were observed in the present
work with oxantel pamoate-pyrantel pamoate against T. muris in
vitro, hence this combination was not pursued further. However,
we cannot exclude a better trichuricidal effect in vivo for this
combination, in particular as a pharmacodynamic interference at
Figure 2. Dose response relationship of oxantel pamoate
combinations against T. muris in vitro. Oxantel pamoate-levami-
sole (blue line), oxantel pamoate-ivermectin (green line), oxantel
pamoate-mebendazole (red line), oxantel pamoate-pyrantel pamoate
(pink line) and oxantel pamoate-albendazole (orange line) were
combined using ratios based on their IC50s.
doi:10.1371/journal.pntd.0002119.g002
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the target is unlikely. Oxantel is classified as an N-subtype AChR
agonist, while pyrantel is considered an L-subtype suggesting
differences in drug action [35]. The combination of oxantel
pamoate-pyrantel pamoate is widely used in veterinary medicine
and has also been studied in several human clinical trials. For
example, in Korea oxantel pamoate-pyrantel pamoate at 20 mg/
kg achieved a cure rate of 75% and egg reduction rate of 97%
against T. trichiura infections and cleared A. lumbricoides infections
[13]. A high egg reduction rate against T. trichiura following
oxantel pamoate-pyrantel pamoate at 20 mg/kg was also reported
in a Malaysian study [18]. A lower effect of this combination
administered at 10 mg/kg was observed on Pemba with cure rates
of 96.3, 38.2 and 12.7% against A. lumbricoides, T. trichiura and
hookworm, respectively [19]. In two Korean trials both oxantel
monotherapy as well as an oxantel-pyrantel combination were
used, however since different formulations were used (syrup versus
tablets), different dosages applied and sample sizes were small no
conclusion can be drawn whether the combination was superior to
oxantel monotherapy [13,14].
Antagonistic effects were observed in vivo using combinations of
oxantel pamoate-albendazole, oxantel pamoate-levamisole and
oxantel pamoate-ivermectin. Since the molecular basis for the
actions of these drugs is not yet fully elucidated it is impossible to
explain the antagonistic interaction profile observed for these
combinations. On the other hand, the oxantel pamoate-meben-
dazole combination revealed highly synergistic effects against T.
muris in vivo. It is striking that the two benzimidazole derivates
behave so differently when administered as partner drugs in
oxantel pamoate combinations to T. muris infected mice given that
both drugs, despite their differences in pharmacokinetics [36],
have identical targets. However, our results should be interpreted
with caution. First of all, drug scheduling and drug vehicle,
solubility, host behavior, environmental factors and genetic
variations might influence the level of activity [37]. In addition,
though the median effect method used in the present work is the
most commonly used, our data are based on a single method only
and one could have considered applying another method, such as
the isobologram method to re-analyze the data [38]. Finally, note
that these findings are based on a single ratio of the combined
agents (ED50 values) and it might be worthwhile to assess other
ratios of the drug dosages.
In conclusion, our study confirms that oxantel pamoate has
excellent trichuricidal properties. In the T. muris mouse model
oxantel pamoate showed a higher activity than the standard drugs
albendazole, mebendazole, levamisole and pyrantel pamoate.
Since the drug has no activity against hookworms it is necessary to
combine oxantel pamoate with a partner drug revealing anti-
hookworm properties. Synergistic effects were observed for oxantel
pamoate-mebendazole. Despite of our results pointing to an
antagonistic behavior of oxantel pamoate-albendazole additional
investigations on the effect of this combination might be
considered (e.g. evaluation of a different dosing ratio or schedule)
since of the standard drugs albendazole has the highest efficacy
against hookworms [5]. Systemic drug interactions between
oxantel pamoate and partner drugs are unlikely given that the
absorption of oxantel pamoate is very poor [11]. Nonetheless,
preclinical studies should carefully elucidate metabolic and
pharmacokinetic interactions of oxantel pamoate and the benz-
imidazoles.
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